BRIEF-Akari Therapeutics' Preclinical Data Demonstrates The Potential Of Its Novel ADC Spliceosome Modulating Payload, Ph1

Reuters

Sep 24

BRIEF-Akari <a href="https://laohu8.com/S/LENZ">Therapeutics</a>' Preclinical Data Demonstrates The Potential Of Its Novel ADC Spliceosome Modulating Payload, Ph1

Sept 24 (Reuters) - Akari Therapeutics PLC AKTX.O:

AKARI THERAPEUTICS’ PRECLINICAL DATA DEMONSTRATES THE POTENTIAL OF ITS NOVEL ADC SPLICEOSOME MODULATING PAYLOAD, PH1
AKARI : PLANS TO TEST AGAINST DIFFERENT PROSTATE CANCER TARGETS THE HYPOTHESIS THAT ARPI PLUS PH1 ADCS MAY SLOW DEVELOPMENT OF RESISTANCE

Source text: ID:nGNX9td05g

Further company coverage: AKTX.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2569077702"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569077702\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569077702?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 21:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569077702","market":"us","top_or_hot":-1,"title":"BRIEF-Akari Therapeutics' Preclinical Data Demonstrates The Potential Of Its Novel ADC Spliceosome Modulating Payload, Ph1","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Akari <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' Preclinical Data Demonstrates The Potential Of Its Novel ADC Spliceosome Modulating Payload, Ph1</title></head><body><p><span>Sept 24 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/AKTX\">Akari Therapeutics PLC</a> <span>AKTX.O</span>:</p><ul><li><p>AKARI THERAPEUTICS’ PRECLINICAL DATA DEMONSTRATES THE POTENTIAL OF ITS NOVEL ADC SPLICEOSOME MODULATING PAYLOAD, PH1</p></li><li><p>AKARI : PLANS TO TEST AGAINST DIFFERENT PROSTATE CANCER TARGETS THE HYPOTHESIS THAT ARPI PLUS PH1 ADCS MAY SLOW DEVELOPMENT OF RESISTANCE</p></li></ul><p>Source text: <span>ID:nGNX9td05g</span></p><p>Further company coverage: <span>AKTX.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Akari Therapeutics' Preclinical Data Demonstrates The Potential Of Its Novel ADC Spliceosome Modulating Payload, Ph1</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Akari Therapeutics' Preclinical Data Demonstrates The Potential Of Its Novel ADC Spliceosome Modulating Payload, Ph1\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-24 21:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Akari <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' Preclinical Data Demonstrates The Potential Of Its Novel ADC Spliceosome Modulating Payload, Ph1</title></head><body><p><span>Sept 24 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/AKTX\">Akari Therapeutics PLC</a> <span>AKTX.O</span>:</p><ul><li><p>AKARI THERAPEUTICS’ PRECLINICAL DATA DEMONSTRATES THE POTENTIAL OF ITS NOVEL ADC SPLICEOSOME MODULATING PAYLOAD, PH1</p></li><li><p>AKARI : PLANS TO TEST AGAINST DIFFERENT PROSTATE CANCER TARGETS THE HYPOTHESIS THAT ARPI PLUS PH1 ADCS MAY SLOW DEVELOPMENT OF RESISTANCE</p></li></ul><p>Source text: <span>ID:nGNX9td05g</span></p><p>Further company coverage: <span>AKTX.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nFWN3VB02A:1","article_id":"2569077702","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569077702","pubTimestamp":1758721317,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Akari Therapeutics' Preclinical Data Demonstrates The Potential Of Its Novel ADC Spliceosome Modulating Payload, Ph1Sept 24 (Reuters) - Akari Therapeutics PLC AKTX.O:AKARI THERAPEUTICS’ PRECLINI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AKTX":"Akari Therapeutics PLC","BK4007":"制药"},"translate_title":"简介-Akari Therapeutics的临床前数据证明了其新型ADC剪接体调节有效负载Ph1的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKTX":0.9},"content_text":"BRIEF-Akari Therapeutics' Preclinical Data Demonstrates The Potential Of Its Novel ADC Spliceosome Modulating Payload, Ph1Sept 24 (Reuters) - Akari Therapeutics PLC AKTX.O:AKARI THERAPEUTICS’ PRECLINICAL DATA DEMONSTRATES THE POTENTIAL OF ITS NOVEL ADC SPLICEOSOME MODULATING PAYLOAD, PH1AKARI : PLANS TO TEST AGAINST DIFFERENT PROSTATE CANCER TARGETS THE HYPOTHESIS THAT ARPI PLUS PH1 ADCS MAY SLOW DEVELOPMENT OF RESISTANCESource text: ID:nGNX9td05gFurther company coverage: AKTX.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}